Latest Libertus Capital News
Jul 12, 2021
BillionToOne, Inc. , a Menlo Park, Calif.-based molecular diagnostics company, closed a $55m Series B funding round. The round, announced in June 2021, was led by existing investor Hummingbird Ventures and incoming investor Four Rivers Group with participation from Neotribe Ventures, Norwest Venture Partners, Y Combinator, and Libertus Capital. The company is using the funds to expand its the clinical lab, as well as its commercial team nationwide. Co-founded by Oguzhan Atay, Ph.D. and David Tsao, Ph.D., and also led by Jennifer Hoskovec, MS, CGC, Director of Medical Affairs, BillionToOne is a precision diagnostics company whose its patent-pending QCT molecular counter platform can count DNA molecules at the single-count level. Its flagship product, UNITY, is a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis (CF), spinal muscular atrophy (SMA), and hemoglobinopathies through maternal blood. FinSMEs
Libertus Capital Team
1 Team Member
Libertus Capital has 1 team member, including current Managing Partner, Pamir Gelenbe.